Is EVAX or EXEL more undervalued in 2026?

CirclFi compares Evaxion A/S (EVAX) and Exelixis, Inc. (EXEL) using 13 institutional-grade valuation models. EVAX has a Quality of Company score of 1.9/10 while EXEL scores 10.0/10.

Which is a better buy — EVAX or EXEL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EVAX and EXEL valuations compare?

EVAX at $4.10 and EXEL at $51.45 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EVAX vs EXEL Valuation Comparison 2026 — Intrinsic Value Analysis

EVAX

Biotechnology

Evaxion A/S

Quality

1.9

out of 10

Value Trap

SAFE

Price

$4.10

Last close

Models

7/13

Active

EXEL

Biotechnology

Exelixis, Inc.

Quality

10.0

out of 10

Value Trap

SAFE

Price

$51.45

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	EVAX Fair Value	EVAX Upside	EXEL Fair Value	EXEL Upside
Bayesian DCF	Intrinsic	$1.09	-73.5%	$43.90	-14.7%
Earnings Power Value	Intrinsic	—	—	$29.37	-42.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.18	-95.5%	$44.22	-14.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EVAX vs EXEL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EVAX vs EXEL — Which Stock Is More Undervalued?

EXEL scores higher with a 10.0/10 quality rating vs EVAX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Evaxion A/S (EVAX) and Exelixis, Inc. (EXEL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EVAX currently trades at $4.10 with a QOC of 1.9/10, while EXEL trades at $51.45 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).